Skip to content

Dianthus Therapeutics DNTH Investment Proceeds

Investment Proceeds at other companies

Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$107.75M+50.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$133.86M+0.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$156.69M+38.4%
TG Therapeutics logo
TG TherapeuticsTGTX
$11.25M-86.0%
Biogen logo
BiogenBIIB
$500K
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10M

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's investment proceeds?
Dianthus Therapeutics (DNTH) reported investment proceeds of $104.63M in Q1 2026.
How has Dianthus Therapeutics's investment proceeds changed year-over-year?
Dianthus Therapeutics's investment proceeds increased by 27.4% year-over-year, from $82.14M to $104.63M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.